Ajooni Biotech Limited — Others, 13-02-2025: Statement of deviation(s) or variation(s) under Reg. 32

Ajooni Biotech Limited has issued a statement confirming there are no deviations or variations in the utilization of proceeds from its recent Right Issue, which raised ₹42.31 crore. The funds were assessed for the quarter ended December 31, 2024, and the Audit Committee has reviewed the proper allocation, affirming adherence to the original objectives. This consistent use of funds supports operational stability and reflects sound financial management, which could enhance investor confidence and maintain a positive outlook in the market, reassuring shareholders about fiscal responsibility.